Base de dados : LILACS
Pesquisa : D09.067.342.531 [Categoria DeCS]
Referências encontradas : 36 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 4 ir para página            

  1 / 36 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: lil-676169
Autor: Ajadi, Adetola R; Gazal, Oladele, S; Otesile, Ebenezer, B; Kasali, Olajide, B.
Título: Evaluation of glucosamine and snail mucin on the progression of experimental knee osteoarthritis in dogs / Evaluación de la glucosamina y mucina de caracol en la progresión de la osteoartritis experimental de rodilla en perros
Fonte: Int. j. morphol;31(1):280-286, mar. 2013. ilus.
Idioma: en.
Resumo: This study evaluated the effect of oral glucosamine and intramuscular injection (IM) of snail mucin on the progression of experimental osteoarthritis (OA) in dogs. Twenty adult mongrels with mean body weight (12.4±1.8 kg) were used. Experimental OA was induced surgically using the groove model. The dogs were randomly divided into three groups following radiographic evidence of OA. Group one (control) comprised of ten dogs treated with normal saline twice weekly for four weeks following OA. Group two comprised of five dogs treated with 10mg/kg of oral glucosamine daily for four weeks. Group three comprised of five dogs treated with 5mg/kg intramuscular injection of 5% solution of snail mucin twice weekly for four weeks. Blood was obtained from the cephalic vein before surgical arthrotomy, after surgical arthrotomy, immediately after radiographic confirmation of OA (Week 0) and at two weeks interval up to 4 weeks of treatment. Efficacy of the drugs was assessed by changes in plasma IL-6 and MMP-3, while safety was determined using the changes in packed cell volume (PCV), total white blood cell counts (WBC) and observable adverse reactions associated with the administration of the drugs. In this study, the PCV and WBC did not differ significantly (P> 0.05) from the control group. Plasma IL-6 and MMP-3 were significantly (P< 0.05) lower both in glucosamine-treated and snail mucin-treated dogs up to week 4 of treatment when compared with the control group. However, there were no significant (P > 0.05) differences in IL-6 and MMP-3 between the two treatment groups. In addition, painful swelling at the site of injection was observed in dogs treated with snail mucin, while no adverse reaction was observed in dogs treated with oral glucosamine. It was therefore concluded that both oral glucosamine and IM injection of snail mucin comparably modified the progression of OA. However, owing to the adverse reaction noted with IM injection of snail mucin, further study is required to determine the most appropriate route of administration.

Se evaluaron los efectos de la glucosamina oral y la inyección intramuscular (IM) de mucina de caracol en la progresión de la osteoartritis (OA) experimental en perros. Fueron utilizados 20 perros mestizos adultos con un peso medio de 12,4±1,8 kg. La OA experimental se indujo quirúrgicamente mediante el modelo de ranura. Los animales se dividieron aleatoriamente en tres grupos después de la evidencia radiográfica de OA. El grupo 1 (control, 10 perros) fue tratado con una solución salina normal dos veces por semana durante cuatro semanas. El grupo 2 (5 perros) fue tratado con 10 mg/kg de glucosamina oral al día por cuatro semanas, y el grupo 3 (5 perros) fue tratado con 5 mg/kg IM de una solución de mucina de caracol al 5% dos veces por semana durante cuatro semanas. Se obtuvieron muestras de sangre desde la vena cefálica previo a la artrotomía quirúrgica, después de la artrotomía e inmediatamente después de la confirmación radiográfica de OA (semana 0), y en el intervalo de dos semanas hasta cuatro semanas de tratamiento. La eficacia de los fármacos se evaluó por los cambios plasmáticos de IL-6 y MMP-3, mientras que la seguridad, se determinó por los cambios en el volumen del hematocrito (VH), el recuento total de glóbulos blancos (RGB), y la observación de reacciones adversas asociadas a la administración de fármacos. El VH y RGB no difirieron significativamente (P>0,05) en el grupo control. Los niveles de IL-6 y MMP-3 plasmática fueron significativamente más bajas (P<0,05) en los perros tratados con glucosamina y mucina de caracol hasta 4 semanas, en comparación con el grupo control. Sin embargo, no hubo diferencias significativas (P>0,05) en la IL-6 y MMP-3 entre los dos grupos de tratamiento. Además, se observó un edema doloroso en el sitio de inyección de los perros tratados con mucina de caracol. En los perros tratados con glucosamina oral no se observó reacción adversa. Se concluye que tanto la glucosamina oral y la inyección IM de mucina de caracol modifican comparablemente la progresión de OA. Sin embargo, debido a la reacción adversa observada con la inyección IM de mucina caracol, se necesitan estudios adicionales para determinar la vía de administración más adecuada.
Descritores: Osteoartrite do Joelho
Glucosamina/administração & dosagem
Mucinas/administração & dosagem
-Caramujos/química
Administração Oral
Interleucina-6/sangue
Progressão da Doença
Metaloproteinases da Matriz/sangue
Modelos Animais de Doenças
Injeções
Limites: Animais
Cães
Responsável: CL1.1 - Biblioteca Central


  2 / 36 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1115610
Autor: Zagaceta Torres, Walter; Garavito Rentería, Jorge Luis.
Título: Hepatotoxicidad inducida por glucosamina-condroitina en un hospital público de Lima (Perú): reporte de caso / Case report of glucosamine-chondroitin induced hepatotoxicity in a public hospital in Lima, Peru
Fonte: Rev. colomb. gastroenterol;35(1):130-134, 2020. tab.
Idioma: es.
Resumo: Resumen En el cuerpo humano tenemos glucosamina y condroitina de forma natural. Estas sustancias constituyen un componente importante del sistema cartilaginoso. Como medicamentos, tienen múltiples indicaciones clínicas, principalmente la osteoartritis. La hepatotoxicidad inducida por estas biomoléculas es infrecuente, pues cuentan solo con reportes de casos aislados en la literatura mundial. En este trabajo, presentamos el caso de una paciente con una lesión hepática inducida por glucosamina-condroitina del tipo hepatocelular, que fue admitida en el hospital por causa de una sintomatología respiratoria y malestar general. En ella, se destacó una marcada hipertransaminasemia durante los exámenes de laboratorio. Asimismo, se descartaron etiologías como el alcohol, hepatitis virales y hepatopatías autoinmunes, principalmente. De igual forma, no se llegó a evidenciar una enfermedad hepática crónica mediante la ecografía abdominal. Al suspenderse el medicamento, se observó una disminución considerable de la hipertransaminasemia luego de 1 semana, y una mejoría total de esta a los 2 meses del alta hospitalaria. Este caso se añade a los pocos reportados a nivel mundial y cobra una importancia relevante para la publicación de posteriores estudios sistemáticos que aclaren el panorama de esta enfermedad.

Abstract The human body naturally produces glucosamine and chondroitin which are important components of the cartilaginous system. There are multiple clinical indications for them as medicines, but they are primarily used for osteoarthritis. Hepatotoxicity induced by these biomolecules is uncommon, and the only reports in the world literature are isolated individual cases. This article presents the case of a patient with glucosamine-chondroitin-induced hepatocellular damage who was admitted to the hospital with respiratory symptoms and malaise. Marked hypertransaminemia was found in laboratory tests. Etiologies such as alcohol, viral hepatitis and autoimmune liver diseases were ruled out, and abdominal ultrasound found no evidence of chronic liver disease. Discontinuance of glucosamine and chondroitin led to a considerable decrease in hypertransaminemia after one week with total improvement two months of hospital discharge. This case adds to the small number reported worldwide and is relevant for future systematic studies to clarify the outlook for this disease.
Descritores: Condroitina
Glucosamina
-Osteoartrite
Limites: Humanos
Feminino
Idoso
Tipo de Publ: Relatos de Casos
Responsável: CO354 - Sociedad Colombiana de Gastroenterología


  3 / 36 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1001822
Autor: Coimbra, Ibsen Bellini; Plapler, Pérola Grinberg; Campos, Gustavo Constantino de.
Título: Generating evidence and understanding the treatment of osteoarthritis in Brazil: a study through Delphi methodology
Fonte: Clinics;74:e722, 2019. tab, graf.
Idioma: en.
Resumo: OBJECTIVES: This study aimed to provide evidence for understanding how to treat osteoarthritis (OA) in our country. Therefore, it was necessary to match information and investigations related to the treatment of the disease from the three main types of specialists involved: physiatrists, orthopedists and rheumatologists. METHODS: The authors acted as a scientific advisory committee. From the initial discussions, a structured questionnaire was developed for use with a group of specialists on OA using the Delphi technique. The questionnaire was sent to 21 experts appointed by the authors, and the results obtained were critically analyzed and validated. RESULTS: The prevalence of OA was 33% in Brazil, corresponding to one-third of the individuals in the reference population, which included individuals over 25 years of age. Another significant finding was that most patients did not receive any form of treatment in the early stages of OA. CONCLUSION: The committee pointed to the need for early intervention and that the available medicinal resources can fulfil this important role, as is the case with SYSADOA treatments. Glucosamine-based medicinal products with or without chondroitin could also fulfill this need for early treatment. The other generated evidence and included investigations were then grouped together and are the subject of this publication.
Descritores: Osteoartrite/terapia
Técnica Delfos
Competência Clínica/normas
Medicina Baseada em Evidências/normas
-Ortopedia/normas
Osteoartrite/tratamento farmacológico
Medicina Física e Reabilitação/normas
Índice de Gravidade de Doença
Brasil
Anti-Inflamatórios não Esteroides/administração & dosagem
Sulfatos de Condroitina/uso terapêutico
Resultado do Tratamento
Osteoartrite do Joelho/terapia
Consenso
Quimioterapia Combinada
Glucosamina/uso terapêutico
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME


  4 / 36 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-387792
Autor: Wurcel, Victoria.
Título: Glucosamina en el tratamiento de la artrosis / Glucosamine in the treatment of arthrosis
Fonte: Evid. actual. práct. ambul;6(4):122-123, jul.-ago. 2003. tab.
Idioma: es.
Descritores: Osteoartrite
Glucosamina
-Dor
Ensaios Clínicos como Assunto
Medicina Baseada em Evidências
Cartilagem Articular/patologia
Limites: Humanos
Masculino
Feminino
Idoso
Responsável: AR2.1 - Biblioteca Central


  5 / 36 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-569757
Autor: De Vas, Yanina; Wurcel, Victoria.
Título: Rol de la glucosamina en el tratamiento de la osteoartritis / Role of glucosamine in the treatment of osteoarthritis
Fonte: Evid. actual. práct. ambul;12(1):28-30, ene.-mar. 2009.
Idioma: es.
Resumo: La osteoartritis es una enfermedad degenerativa del cartílago que produce disminución del espacio articular y cambios en el hueso subyacente. Se postula que la administración de glucosamina exógena estimularía la síntesis de matriz cartilaginosa y protegería el hueso. A pesar de esto, no hay evidencia sólida para sostener el uso de glucosamina en la osteoartritis leve.
Descritores: Dor/tratamento farmacológico
Glucosamina/farmacologia
Glucosamina/uso terapêutico
Osteoartrite/diagnóstico
Osteoartrite
Osteoartrite/tratamento farmacológico
Osteoartrite/terapia
Terapêutica
Limites: Humanos
Masculino
Feminino
Responsável: AR2.1 - Biblioteca Central


  6 / 36 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1142497
Autor: Hawas, Asrar Mohamed Mourad; Rashed, Laila Ahmed; Mohamed, Marwa Abd El Hameed.
Título: Evaluation of Glucosamine Effect Against Heart and Brain Damage Induced by Y-radiation or Aluminium Chloride in Female Rats
Fonte: Braz. arch. biol. technol;63:e20180687, 2020. tab, graf.
Idioma: en.
Resumo: Abstract Glucosamine is known as anti-inflammatory, antioxidant and as neuroprotective as well as using to treat many of diseases. This work aimed to investigate the remedial effect of glucosamine (20mg/kg b.wt) against the damage induced by a single dose of γ-radiation (8Gy) or aluminium chloride (AlCl3) (100mg/kg b.wt) in the heart and brain tissues of female rats. Serum aspartate aminotransferase (AST), cholesterol, triglycerides (TGs), LDH and creatine kinase (CPK) were measured. Moreover, gene expression of amyloid protein precursor (APP) and seladin-1 were estimated in the brain tissue. Also, acetylcholinesterase activity (AChE) and p-tau protein expression were estimated in brain homogenate. Metallothioneine (MT) was estimated in the heart and brain tissues. Heart and brain histopathological examination was performed. Irradiation significantly decreased serum AST, CPK and LDH, as well as MT levels in heart and brain tissues. Also, gene expression of seladin-1 decreased. On the other hand, irradiation significantly increased serum TGs level and brain AchE activity, tau protein, and β-amyloid percursor (APP). AlCl3 administration (21 days) induced disturbance in most of the estimated parameters, especially AST, TGs, and MT. Glucosamine treatment with irradiation or AlCl3 improved most of the measured parameters. In addition, histopathological examination confirmed the biochemical results. In conclusion: Glucosamine could be used to improve the heart and brain damages induced by γ-radiation exposure or AlCl3.
Descritores: Encefalopatias/tratamento farmacológico
Doenças Cardiovasculares/tratamento farmacológico
Exposição à Radiação/efeitos adversos
Cloreto de Alumínio/efeitos adversos
Glucosamina/uso terapêutico
Anti-Inflamatórios/uso terapêutico
-Encefalopatias/etiologia
Encefalopatias/patologia
Doenças Cardiovasculares/etiologia
Doenças Cardiovasculares/patologia
Reação em Cadeia da Polimerase
Ratos Wistar
Modelos Animais de Doenças
Limites: Animais
Feminino
Ratos
Responsável: BR1.1 - BIREME


  7 / 36 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Silva, Antônio Carlos da
Radominski, Sebastiäo Cezar
Texto completo
Id: biblio-1152749
Autor: Lomonte, Andrea Barranjard Vannucci; Gimenez, Emerson; Silva, Antônio Carlos da; Radominski, Sebastião Cezar; Scheinberg, Morton Aaron; Ximenes, Antônio Carlos; Zerbini, Cristiano Augusto de Freitas.
Título: Treatment of knee osteoarthritis with a new formulation of a fixed-dose combination of glucosamine sulfate and bovine chondroitin: a multicenter, randomized, single-blind, non-inferiority clinical trial
Fonte: Adv Rheumatol;61:7, 2021. tab, graf.
Idioma: en.
Resumo: Abstract Objectives: To compare the efficacy and safety of a new formulation of a fixed dose combination of glucosamine sulfate (GS; 1500 mg) and bovine chondroitin sulfate (CS; 1200 mg) versus the reference product (RP) in patients with knee osteoarthritis (OA). Methods: In this multicenter, randomized, single-blind trial, 627 patients with knee osteoarthritis (OA)—Kellgren-Lawrence grades 2 or 3 and mean score ≥ 40 mm in the WOMAC pain subscale—were randomized to receive GS/ CS or the RP for 24 weeks. The primary efficacy endpoint was the absolute change in WOMAC pain subscale score. The secondary endpoints included the following: WOMAC total and subscale scores, overall assessment of the disease by the patient and the investigator, SF-12 score, OMERACT-OARSI response rate to the treatment, and rescue medication use. Results: Mean reductions of WOMAC pain score were - 35.1 (sd = 23.2) mm in the GS/CS group and - 36.5 (sd = 24.9) mm in the RP group. The difference between the adjusted means of both treatments confirmed the noninferiority of GS/CS versus the RP. Improvement was observed in pain, stiffness, physical function and total WOMAC score, as well as in overall OA assessment by the patient and the investigator for both groups. No improvement was observed in SF-12. The rate of OMERACT-OARSI responders was 89.4% in GS/CS group and 87.9% in the RP group. Headache and changes in glucose tolerance were the most frequent treatment-related adverse events. Conclusions: The new formulation of a fixed-dose combination of glucosamine sulfate and bovine chondroitin sulfate was non-inferior to the RP in symptomatic treatment of knee OA, with a high responder rate and good tolerability profile. Trial registration: ClinicalTrials.gov; Registration number NCT02830919; Date of registration: July 13, 2016; First randomization date: December 05, 2016).(AU)
Descritores: Condroitina/uso terapêutico
Osteoartrite do Joelho/tratamento farmacológico
Combinação de Medicamentos
Glucosamina/uso terapêutico
-Método Simples-Cego
Resultado do Tratamento
Limites: Humanos
Tipo de Publ: Estudo Multicêntrico
Ensaio Clínico Controlado Aleatório
Responsável: BR1.1 - BIREME


  8 / 36 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-915053
Autor: Sanhueza M, Lilian; Moreno, Daniel; Durruty A, Pilar.
Título: Formoline L112® asociado a terapia no farmacológica en el manejo de la obesidad en diabéticos y prediabéticos / Formoline L112® associated with non pharmacological therapy in the management of obesity in diabetic and prediabetic patients
Fonte: Rev. chil. endocrinol. diabetes;11(3):91-96, jul. 2018. graf, tab.
Idioma: es.
Descritores: Diabetes Mellitus/tratamento farmacológico
Glucosamina/uso terapêutico
Hipolipemiantes/uso terapêutico
Obesidade/tratamento farmacológico
-Estado Pré-Diabético/tratamento farmacológico
Doenças Cardiovasculares/prevenção & controle
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Responsável: CL1.1 - Biblioteca Central


  9 / 36 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Borges, A. P. B
Texto completo
Texto completo
Id: lil-747063
Autor: Eleotério, R. B; Pontes, K. C. S; Machado, J. P; Reis, E. C. C; Ferreira, P. S; Silva, M. B; Martins, N. J. S; Fernandes, N. A; Borges, A. P. B.
Título: Chondroitin sulfate and glucosamine in the cartilage and subchondral bone repair of dogs - Histological findings / Sulfato de condroitina e glucosamina na reparação da cartilagem e do osso subcondral de cães - Achados histológicos
Fonte: Arq. bras. med. vet. zootec;67(2):325-333, Mar-Apr/2015. tab, ilus.
Idioma: en.
Resumo: Chondroitin and glucosamine sulfate nutraceuticals are commonly used in the management of degenerative articular disease in veterinary routine. However, there are controversies on the contribution of these substances to articular cartilage. The purpose of this study was to evaluate the efficiency of a chondroitin and glucosamine sulfate-based veterinary nutraceutical on the repair of an induced osteochondral defect in a dog femoral condyle, by macroscopic, histological and histomorphometric analyses. The nutraceutical was orally administered the day following injury induction, every 24 hours (treated group, TG, n=24), compared with animals that did not receive the product (control group, CG, n=24). Six animals per group were anaesthetized for sample collection at 15, 30, 60 and 90 days after surgery. At 15 days, defects were macroscopically filled with red-pinkish tissue. After 30 days, whitish color tissue was observed, both in TG and CG animals, with firmer consistency to touch at 60 and 90 postoperative days. Histological analysis demonstrated that, in both groups, there was initial blood clot formation, which was subsequently substituted by a fibrin net, with capillary proliferation from the adjacent bone marrow and infiltration of mesenchymal cells in clot periphery. As cellular differentiation developed, repair tissue presented a fibrocartilage aspect most of the time, and new subchondral bone formation occurred in the deepest area corresponding to the defect. Histomorphometry suggested that the nutraceutical did not favor the articular cartilage repair process. It was concluded that nutraceutical did not significantly influence chondrocytes proliferation or hyaline architecture restoration.(AU)

Os nutracêuticos compostos de sulfato de condroitina e glucosamina são comumente utilizados no manejo da doença articular degenerativa na rotina veterinária. Entretanto, existem controvérsias sobre a contribuição dessas substâncias à cartilagem articular. O objetivo deste trabalho foi avaliar a eficácia de um nutracêutico veterinário à base de sulfato de condroitina e glucosamina na reparação de defeitos osteocondrais induzidos no côndilo femoral de cães, através de análises macroscópica, histológica e histomorfométrica. O nutracêutico foi administrado no dia seguinte à indução da lesão, pela via oral, a cada 24 horas (grupo tratado - GT, 24 animais), sendo comparado a animais que não receberam o produto (grupo controle - GC, de igual número de animais). Aos 15, 30, 60 e 90 dias após a cirurgia, seis animais por grupo foram anestesiados para ser realizada a coleta das amostras. Aos 15 dias, os defeitos eram macroscopicamente preenchidos por tecido de coloração rósea a avermelhada. Já a partir dos 30 dias, observou-se preenchimento por tecido de coloração esbranquiçada, tanto nos animais do GT quanto nos do GC, com consistência mais firme ao toque digital aos 60 e 90 dias de pós-operatório. A análise histológica revelou que, em ambos os grupos, houve inicialmente formação de coágulo sanguíneo que, posteriormente, foi substituído por uma rede de fibrina, com proliferação de capilares a partir da medula óssea adjacente e infiltração de células mesenquimais na periferia do coágulo. À medida que se processou a diferenciação celular, o tecido de reparação se apresentou na maioria das vezes com aspecto de fibrocartilagem e, na região mais profunda da área correspondente ao defeito, ocorreu formação de osso novo subcondral. A histomorfometria sugeriu que o nutracêutico não favoreceu o processo de reparação da cartilagem articular. Concluiu-se que o nutracêutico não influenciou consideravelmente na proliferação de condrócitos nem na restauração da arquitetura hialina.(AU)
Descritores: Osteoartrite/veterinária
Doenças das Cartilagens/veterinária
Sulfatos de Condroitina/uso terapêutico
Artroplastia Subcondral/veterinária
Glucosamina/uso terapêutico
Artropatias/veterinária
Limites: Animais
Cães
Responsável: BR68.1 - Biblioteca Virginie Buff D'Ápice


  10 / 36 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: lil-732994
Autor: Alvarado, Cornelio Barrientos; Vázquez, Jorge Sánchez; Oscoy, María Atanasia Silvia Cárdenas; Acosta, Osvaldo Garrido; Robledo, Liliana Anguiano.
Título: Efecto de la administración subcrónica de glucosamina oral en la regulación del peso corporal, glucemia y dislipidemias provocada por una dieta hipercalórica en rata Wistar / Effect of subchronic oral administration of glucosamine in the regulation of body weight, glycemia and dyslipidemia induced hypercholesterolemic Wistar rat
Fonte: Rev. Nutr. (Online);27(6):689-701, Nov.-Dec. 2014. tab, graf.
Idioma: es.
Projeto: Instituto Politécnico Nacional.
Resumo: Objetivo: Este estudio evaluó el efecto de la glucosamina oral en el sobrepeso y dislipidemia provocada por una dieta hipercalórica en ratas. Métodos: En 4 grupos de ratas Wistar: alimentados con dieta comercial para roedores y agua de beber sin grupo de control y con glucosamina (500 mg/kg-1 por día) grupo glucosamina y con dieta hipercalórica enriquecida al 24% (g/g) compuesta por manteca de cerdo y agua de beber sin grupo hipercalórico y con glucosamina grupo hipercalórico + grupo glucosamina, durante 22 semanas, se evaluaron el peso corporal, grasa abdominal, niveles de glucemia, triglicéridos, colesterol total y lipoproteínas de alta densidad en suero. Resultados: Se observó un aumento del peso corporal y glucemia en suero con dislipidemias en el grupo con dieta hipercalórica grupo hipercalórico versus grupo de controle (p<0.001); al administrarse glucosamina para esta misma dieta grupo hipercalórico + grupo glucosamina se minimizaron los efectos presentados, disminuyendo la cantidad de grasa abdominal y los niveles del perfil lípido en suero (p>0.05) y regulándose el peso corporal, las lipoproteínas de alta densidad y la glucemia basal (p<0.05). Conclusion: La glucosamina reguló el peso corporal y la glucemia en sangre y minimizó las dislipidemias provocadas por la dieta hipercalórica, favoreciendo el aumento de colesterol lipoproteínas de ...

Objective: This study evaluated the effect of oral glucosamine on overweight and dyslipidemia caused by a high-fat diet in rats. Methods: Four groups of Wistar rats: fed with commercial rodent food and drinking water without (control group) and with glucosamine (500 mg kg-1 per day) and a high-fat diet enriched with 24% (g/g) butter pork and drinking water without and with glucosamine, for 22 weeks; the body weight, abdominal fat, blood glucose, triglycerides, total cholesterol, and high density lipoprotein in serum were evaluated. Results: Body weight gain, increased blood glucose levels and dyslipidemia were observed in the high-fat diet group versus the control group (p<0.001). When glucosamine was administered the same diet the effects were minimized, with a decrease in the amount of abdominal-fat and lipid profile levels in serum (p>0.05), regulated body weight, and high density lipoprotein and glycaemia (p<0.05). The glucosamine did not affect body weight and lipid metabolism in rats when administered with a normal diet. Conclusions: Glucosamine regulated the body weight blood glucose and dyslipidemia caused by a high-fat diet, favoring increased high density lipoprotein cholesterol in rats. It did not affect body weight and lipid metabolism when administered with commercial food. .
Descritores: Glicemia/efeitos dos fármacos
Dieta Hiperlipídica/efeitos adversos
Glucosamina/sangue
-Peso Corporal/efeitos dos fármacos
Ratos Wistar/sangue
HDL-Colesterol/sangue
Limites: Animais
Masculino
Ratos
Responsável: BR13.3 - Biblioteca das Faculdades de Odontologia e Nutrição



página 1 de 4 ir para página            
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde